News

The funds will support the clinical and regulatory development of ridinilazole for the treatment of CDI, including Summit’s planned Phase 3 development program. Ridinilazole is a highly selective,

“The results presented today demonstrate that IRX-2, a primary cell-derived biologic, drives intratumoral immune infiltration of T cells, B cells and dendritic cells, promoting their activation. “This increase

According to the agreement, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to discover novel leads which will be licensed exclusively

The Johnson & Johnson company said that by stopping development of JNJ-4178, its investigational hepatitis C treatment regimen, it would focus on addressing significant unmet needs in chronic

 The collaboration will bring together Gubra’s expertise in the design, synthesis, characterization and in in vivo testing of therapeutic peptides with Boehringer Ingelheim’s expertise in the development of

The Israeli pharma firm said that fremanezumab showed statistically significant and clinically meaningful results in the phase 3 studies in chronic (CM) and episodic migraine (EM). It added

The loan agreement is operated under the European Fund of Strategic Investments ("EFSI"). EFSI is an essential pillar of the Investment Plan for Europe ("IPE"), under which the

The approval has been granted for cemiplimab to treat adults with metastatic CSCC and adults with locally advanced and unresectable CSCC. CSCC is claimed to be the second

The company also revealed that it will be shuttering its Bridgewater research and development office in New Jersey along with the Lilly China Research and Development Center in